Startup Orbital Therapeutics brings Bristol Myers Squibb an in vivo cell therapy in development for treating autoimmune disease. With the deal, BMS joins AstraZeneca, AbbVie, and Gilead Sciences in turning to M&A as a way to get in vivo cell therapy assets and technologies.
Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in the emerging class of FGF21 analogs for the fatty liver disease MASH. The deal comes months after Novo’s internal FGF21 drug candidate failed a Phase 2 trial.
Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.
Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns.
Pfizer is acquiring Metsera and its pipeline of obesity medications that could offer dosing and tolerability advantages for patients as well as a manufacturing edge for the pharma giant. Key data Phase 2 readouts for Metsera’s lead GLP-1 drug candidate are expected in 2026.
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller.
Novartis is getting Tourmaline Bio’s pacibekitug, a Phase 3-ready antibody drug in development for atherosclerotic cardiovascular disease (ASCVD). Tourmaline licensed pacibekitug from Pfizer, which remains eligible for milestone payments tied to the progress of the drug.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
EVERSANA is merging with Waltz Health under the EVERSANA name. Mark Thierer, co-founder and CEO of Waltz Health, will serve as the CEO of the combined company.
Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics. The deal follows AstraZeneca and AbbVie acquisitions this year for in vivo cell therapy developers.
Datavant acquired Ontellus, a health records retrieval and claims intelligence company. This establishes a legal and insurance vertical to go along with Datavant’s three other verticals: payers, providers and life sciences firms.
Sanofi’s Vicebio acquisition brings technology for developing vaccine combinations for multiple pathogens, such as RSV and hMPV. The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
Hospital M&A activity slowed quite a bit in the first half of 2025, with deal volume and transacted revenue falling sharply amid economic uncertainty and sweeping policy changes. While traditional mergers may remain sluggish, analysts expect a rise in outpatient partnerships and rural hospital conversions toward the end of the year.
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product in COPD alone, its potential extends to other respiratory disorders as well.
Samsung announced plans to acquire Xealth, a startup that helps hospitals integrate digital tools into clinical workflows, as part of its broader push into U.S. healthcare. The deal reflects growing provider demand for tech solutions and comes amid newfound optimism in the digital health exit market.
Nordic Capital acquired a majority stake in health data platform Arcadia. Together, the two aim to accelerate the company’s mission of advancing value-based care through AI and data analytics. Arcadia CEO Michael Meucci views the deal as both a validation of the company’s strategy and part of a broader wave of healthcare investments focused on interoperability, AI and payment reform.
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.